Twenty-seven patients had AML with TP53 mutation, 13 patients were treated in AFTER and achieved a CR/CRi rate of 46%, whereas CR/CRi rate in the remaining patients was only 21% (p = 0.23). Here, TP53 is linked to acute myeloid leukemia.